Cognitive profile of LRRK2-related Parkinson's disease

Movement Disorders

Volumn 30, Issue 5, 2015, Pages 728-733

  Srivatsal, Sindhu ^a   Cholerton, Brenna ^b,c   Leverenz, James B ^d   Wszolek, Zbigniew K ^e   Uitti, Ryan J ^e   Dickson, Dennis W ^e   Weintraub, Daniel ^f,g   Trojanowski, John Q ^f   Van Deerlin, Vivianna M ^f   Quinn, Joseph F ^h,i   Chung, Kathryn A ^h,i   Peterson, Amie L ^h,i   Factor, Stewart A ^j   Wood Siverio, Cathy ^j   Goldman, Jennifer G ^k   Stebbins, Glenn T ^k   Bernard, Bryan ^k   Ritz, Beate ^l,m   Rausch, Rebecca ^m   Espay, Alberto J ⁿ   Revilla, Fredy J ⁿ   Devoto, Johnna ⁿ   Rosenthal, Liana S ^o   Dawson, Ted M ^o   Albert, Marilyn S ^o   Mata, Ignacio F ^b   Hu, Shu Ching ^b,c   Montine, Kathleen S ^c   Johnson, Catherine ^p   Montine, Thomas J ^c   Edwards, Karen L ^p   Zhang, Jing ^c   Zabetian, Cyrus P ^b,c   more..

^a Virginia Mason Cancer Institute   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h PORTLAND VA MEDICAL CENTER   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k RUSH UNIVERSITY MEDICAL CENTER   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^o JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Cognition; LRRK2; Neuropsychological tests; Parkinson's disease; Working memory

Indexed keywords

LEUCINE RICH REPEAT KINASE 2; LRRK2 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

ARTICLE; COGNITION; CROSS-SECTIONAL STUDY; DEMENTIA; DISEASE ASSOCIATION; GENE MUTATION; HEREDITY; HUMAN; LEUCINE RICH REPEAT KINASE 2 RELATED PARKINSON DISEASE; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PERFORMANCE; PRIORITY JOURNAL; ADULT; AGED; COGNITION DISORDERS; COHORT ANALYSIS; COMPLICATION; FEMALE; GENETICS; MALE; MENTAL HEALTH; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TEST; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MENTAL STATUS SCHEDULE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES;

EID: 84927028813     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26161     Document Type: Article

References (37)

1. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004;61:1906-1911.
2. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21:1343-1349.
3. Alcalay RN, Caccappolo E, Mejia-Santana H, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology 2012;78:1434-1440.
4. Chahine LM, Qiang J, Ashbridge E, et al. Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol 2013;70:852-858.
5. Mata I, Leverenz J, Weintraub D, et al. Variations in APOE, but not MAPT or SNCA, predicts cognitive performance in Parkinson's disease. JAMA Neurol 2014;71:1405-1412.
6. Pankratz N, Byder L, Halter C, et al. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. Mov Disord 2006;21:45-49.
7. Tsuang D, Leverenz JB, Lopez OL, et al. APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol 2013;70:223-228.
8. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008;7:583-590.
9. Kay DM, Zabetian CP, Factor SA, et al. Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord 2006;21:519-523.
10. Yahalom G, Orlev Y, Cohen OS, et al. Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation. Mov Disord 2014.
11. Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005;128:2786-2796.
12. Aasly JO, Toft M, Fernandez-Mata I, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005;57:762-765.
13. Alcalay RN, Mejia-Santana H, Tang MX, et al. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol 2010;32:775-779.
14. Ben Sassi S, Nabli F, Hentati E, et al. Cognitive dysfunction in Tunisian LRRK2 associated Parkinson's disease. Parkinsonism Relat Disord 2012;18:243-246.
15. Lesage S, Ibanez P, Lohmann E, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005;58:784-787.
16. Belarbi S, Hecham N, Lesage S, et al. LRRK2 G2019S mutation in Parkinson's disease: a neuropsychological and neuropsychiatric study in a large Algerian cohort. Parkinsonism Relat Disord 2010;16:676-679.
17. Goldwurm S, Zini M, Di Fonzo A, et al. LRRK2 G2019S mutation and Parkinson's disease: a clinical, neuropsychological and neuropsychiatric study in a large Italian sample. Parkinsonism Relat Disord 2006;12:410-419.
18. Lohmann E, Leclere L, De Anna F, et al. A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations. Parkinsonism Relat Disord 2009;15:273-276.
19. Shanker V, Groves M, Heiman G, et al. Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease. Mov Disord 2011;26:1875-1880.
20. Estanga A, Rodriguez-Oroz MC, Ruiz-Martinez J, et al. Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2. Parkinsonism Relat Disord 2014;20:1097-1100.
21. Mata IF, Cosentino C, Marca V, et al. LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat Disord 2009;15:370-373.
22. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
23. Kang GA, Bronstein JM, Masterman DL, Redelings M, Crum JA, Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005;20:1133-1142.
24. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
25. Benedict RHB, Schretlen D, Groninger L, Brandt J. The Hopkins Verbal Learning Test-Revised: Normative data and analysis of inter-form and inter-rater reliability. The Clinical Neuropsychologist 1998;12:43-55.
26. Wechsler D. WAiS-III® Administration and Scoring Manual. San Antonio, TX: The Psychological Corporation Harcourt Brace & Company, 1997.
27. Army Individual Test Battery: Manual of directions and scoring. Washington, DC: War Department, Adjutant General's Office, 1944.
28. Tombaugh TN, Kozak J, Rees L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol 1999;14:167-177.
29. Benton AL, Sivan AB, Hamsher K, Varney N, Spreen O. Contributions to Neuropsychological Assessment-A Clinical Manual. Lutz, FL: Psychological Assessment Resources, 1994.
30. Cholerton BA, Zabetian CP, Quinn JF, et al. Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis 2013;3:205-214.
31. Goldman JG, Holden S, Bernard B, Ouyang B, Goetz CG, Stebbins GT. Defining optimal cutoff scores for cognitive impairment using Movement Disorder Society Task Force criteria for mild cognitive impairment in Parkinson's disease. Mov Disord 2013;28:1972-1979.
32. Trinh J, Amouri R, Duda JE, et al. Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism. Neurobiol Aging 2014;35:1125-1131.
33. Poulopoulos M, Cortes E, Vonsattel JP, et al. Clinical and pathological characteristics of LRRK2 G2019S patients with PD. J Mol Neurosci 2012;47:139-143.
34. Paisan-Ruiz C, Lewis PA, Singleton AB. LRRK2: cause, risk, and mechanism. J Parkinsons Dis 2013;3:85-103.
35. Kalia LV, Lang AE, Hazrati LN, et al. Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. JAMA Neurol 2014. DOI: 10.1001/jamaneurol.2014.2704.
36. Aarsland D, Perry R, Brown A, Larsen JP, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Ann Neurol 2005;58:773-776.
37. Irwin DJ, White MT, Toledo JB, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol 2012;72:587-598.